Učitavanje...
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness
Rituximab (375 mg/m(2)) achieved remission of the first episode and six relapses of nephrotic syndrome (NS) in a young male patient with podocyte phospholipase A(2) receptor (PLA(2)R)-related membranous nephropathy (MN) refractory to steroids and cyclosporine. Between-treatments interval averaged 17...
Spremljeno u:
| Izdano u: | BMJ Case Rep |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMJ Publishing Group
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7035801/ https://ncbi.nlm.nih.gov/pubmed/31980477 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2019-232896 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|